GLP1R and cardiovascular disorder: Table 4 presents the expected changes in DALYs lost across scenarios per 1,000 person-years in the overall country population, accounting for the portion of the overall population taking insulin at the time of the survey, and the reduced frequency of severe hypoglycemia, cardiovascular disease, renal disease, and overall mortality in both GLP-1 receptor agonist and SGLT-2 inhibitor cases.